Join to View Full Profile
1 Medical Center DriveLebanon, NH 03756
Phone+1 603-650-6432
Fax+1 603-727-7861
Dr. Shirai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Medical University of South CarolinaFellowship, Hematology and Medical Oncology, 2005 - 2008
UPMC Medical EducationResidency, Internal Medicine, 2002 - 2005
Faculty of Medicine Kyoto UniversityClass of 1997
Certifications & Licensure
NH State Medical License 2015 - 2027
VT State Medical License 2023 - 2026
SC State Medical License 2005 - 2017
PA State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2017
Clinical Trials
- NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer Start of enrollment: 2007 Jun 04
- Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Start of enrollment: 2009 Nov 01
- Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2009 Dec 16
Publications & Presentations
PubMed
- A genomic signature predictive of brain metastases in melanoma: Insights from the MSK-MET cohort.Amber Loren O King, Victor Lee, Keisuke Shirai, James B Yu, Brian J Simmons
Journal of the American Academy of Dermatology. 2026-02-01 - Long-term immune checkpoint inhibition therapy for advanced stage Merkel cell carcinoma.Marisa R Diiorio, Nicole Trepanowski, Payal Shah, Keisuke Shirai
JAAD Case Reports. 2026-01-01 - A cytokine-based serum proteomic score is a prognostic biomarker for immunotherapy in head and neck cancer.Md Saiful Islam Saif, Kartik Sehgal, Ze Zhang, Rondi A Butler, John K Wiencke
Cancer Immunology, Immunotherapy. 2025-12-24
Press Mentions
Resident and Circulating Memory T Cells Persist for Years in Melanoma Patients with Durable Responses to ImmunotherapyMarch 24th, 2021
At the Hospitals: Aug. 18, 2019August 17th, 2019
Dartmouth-Hitchcock Health Funds $1M Annually for Dedicated Cancer Clinician Research TimeJuly 31st, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
